Document is current

Article History

Accepted: 23 April 2025

First Online: 7 May 2025

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: Robyn Okereke shares no potential conflicts of interest relevant to this article were reported. The following include disclosures from Eric Simpson: reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics, Bristol Myers Squibb – BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, Leo, Merck, NUMAB Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roivant, Sanofi-Genzyme, SITRYX Therapeutics, Trevi therapeutics, Valeant and reports grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, Target, VeriSkin.